SCHEMBL2996643

SCHEMBL2996643

COC(=O)CC(NC(=O)OC(C)(C)C)c1ccc(OCc2ccccc2)c(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.51
KMT2A Q03164 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
F2 P00734 3/20 0.46
F10 P00742 3/20 0.46
PRSS1 P07477 3/20 0.46
F7 P08709 3/20 0.46
PRSS2 P07478 1/20 0.46
F3 P13726 1/20 0.46
PRSS3 P35030 1/20 0.46
HPGD P15428 3/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 2/20 0.46
HTT P42858 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
MEN1 O00255 3/20 0.46
GAA P10253 1/20 0.46
NPSR1 Q6W5P4 2/20 0.45
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2996725 0.93 POLB (0.60) POLBKMT2ASMN1; SMN2F2F10
SCHEMBL2987962 0.89 NPSR1 (0.48) POLBKMT2ASMN1; SMN2F2F10
SCHEMBL2995448 0.88 NPSR1 (0.49) POLBKMT2ASMN1; SMN2F2F10
SCHEMBL22703470 0.83 PTPN1 (0.42) HPGDALDH1A1HTTRAB9ANPSR1
SCHEMBL31314669 0.83 PTPN1 (0.42) HPGDALDH1A1HTTRAB9ANPSR1
SCHEMBL25976304 0.83 PTPN1 (0.42) HPGDALDH1A1HTTRAB9ANPSR1
SCHEMBL3350832 0.81 POLB (0.61) POLBKMT2ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL3355755 0.80 POLB (0.47) POLBKMT2ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL2996641 0.79 SYK (0.48) POLBKMT2ASMN1; SMN2F2F10
SCHEMBL1783805 0.79 CTSK (0.52) POLBKMT2AHPGDALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2083011-B1 PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF TIANJIN HEMAY BIO TECH CO LTD (CN) 2014-06-04 EP disclosed
US-20100179189-A1 PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF ZHANG HESHENG 2010-07-15 US disclosed
EP-2083011-A1 PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF Tian Jin Hemay Bio-Tech Co., Ltd. (CN) 2009-07-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179189-A1 PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF TNF, IL1B, NOS1 POLB 2466/4885KMT2A 4801/4885SMN1; SMN2 2069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.